Home › Companies › Sarepta Therapeutics, Inc. › 2025-2026

Sarepta Therapeutics, Inc. 2025-2026 Proxy Voting Records

Compiled from SEC Form N-PX filings and Sarepta Therapeutics, Inc.’s Form 8-K, filed 2026-06-04 (Item 5.07 on EDGAR). Page generated 02 October 2026.

11Reported items
356Asset managers
3,299Fund votes
2026-06-04Meeting date

Proxy season: 2023-2024 2024-2025 2025-2026

Explore Sarepta Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Sarepta Therapeutics, Inc.

These tallies are Sarepta Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed 2026-06-04 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX.

Sarepta Therapeutics, Inc. — official shareholder meeting results, meeting held 2026-06-04
Ballot item	For	Against	Abstain	Withheld	Broker non-votes	Outcome
Elect Director: Douglas S. Ingram	66,812,593	827,973	52,441	--	14,616,281	Majority: yes
Elect Director: Hans Wigzell, M.D., Ph.D.	56,984,756	10,663,180	45,071	--	14,616,281	Majority: yes
Elect Director: Kathryn J. Boor, Ph.D.	63,915,239	3,722,626	55,142	--	14,616,281	Majority: yes
Elect Director: Michael Chambers	65,892,431	1,752,077	48,499	--	14,616,281	Majority: yes
Elect Director: Deirdre Connelly	53,419,881	14,213,242	59,884	--	14,616,281	Majority: yes
Proposal 2: Advisory Vote to Approve Named Executive Officer Compensation The stockholders approved, on an advisory basis, the compensation of the Company's named executive officers for 2025	45,185,398	22,373,065	134,544	--	14,616,281	Majority: yes
Proposal 3: Approval of the Company 's 2026 Equity Incentive Plan The stockholders approved the 2026 Plan	63,233,193	4,395,283	64,531	--	14,616,281	Majority: yes
Proposal 4: Approval of the Company 's 2026 Employee Stock Purchase Plan The stockholders approved the 2026 ESPP	67,098,699	532,525	61,783	--	14,616,281	Majority: yes
Proposal 5: Ratification of KPMG as the Company 's Independent Registered Public Accounting Firm The stockholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for the current year ending December 31, 2026	79,907,368	2,110,136	291,784	--	--	Majority: yes

Source: Sarepta Therapeutics, Inc., Form 8-K, filed with the SEC on 2026-06-04 — read the filing on EDGAR.

How asset managers voted at the Sarepta Therapeutics, Inc. 2025-2026 meeting

Each item below shows how the 356 asset managers that disclosed a Sarepta Therapeutics, Inc. vote in their SEC Form N-PX filings actually voted. Share totals are the shares those managers' funds voted, summed across every fund they report. These are reported items, not a count of the ballot: fund filings describe one ballot item in different words. Two descriptions are shown as one item only on evidence — the same text (or one cut short of the other), the same director nominee, or a match to the same row of Sarepta Therapeutics, Inc.’s own Form 8-K tally — never because they merely read alike. A description that could not be joined that way is listed on its own, so one ballot item can appear more than once.

1. Advisory vote to approve, on a non- binding basis, named executive officer compensation

SECTION 14A SAY-ON-PAY VOTESMajority of the votes cast: yes

Meeting held 2026-06-04.

Combines 7 wordings of this item as funds reported it.

67% Majority: yes · of votes cast

FOR 67%AGAINST 33%

FOR: 45,185,398AGAINST: 22,373,065

Sarepta Therapeutics, Inc.’s own tally for this item (“Proposal 2: Advisory Vote to Approve Named Executive Officer Compensation The stockholders approved, on an advisory basis, the compensation of the Company's named executive officers for 2025”): 45,185,398 for, 22,373,065 against, per its Form 8-K filed 2026-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 105,571,146 outstanding shares: 43% for, 21% against (64% of the company cast a for/against vote).

The 352 asset managers below cast 63% of the shares they voted on this item FOR (42,326,370 for, 24,571,492 against).

FOR 63%AGAINST 37%

FOR: 42,326,370 (63.1%)AGAINST: 24,571,492 (36.6%)ABSTAIN: 74,067 (0.1%)NOT VOTED: 74,411 (0.1%)

Largest asset managers voting on “Advisory vote to approve, on a non- binding basis, named executive officer compensation” at Sarepta Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	12,318,385	22,632	1	For
BlackRock	10,210,751	847,229	0	For
State Street	6,186,388	42,657	0	For
First Trust	19	3,925,354	0	Against
RA CAPITAL MANAGEMENT, L.P.	3,902,596	0	0	For
Aberdeen	0	3,279,907	0	Against
Federated Hermes	3,046,814	0	0	For
AQR	0	2,234,115	0	Against
GEODE CAPITAL MANAGEMENT, LLC	1,915,060	0	0	For
T. Rowe Price	0	1,881,553	0	Against
Fidelity	1,699,165	81,376	0	For
Charles Schwab	0	1,465,097	0	Against
CANADA PENSION PLAN INVESTMENT BOARD	0	1,305,900	0	Against
Northern Trust	0	629,344	0	Against
Legal & General Investment Management Ltd	0	600,101	0	Against
Voleon Capital Management LP	0	581,048	0	Against
PRINCIPAL GLOBAL INVESTORS	0	508,797	0	Against
HOTCHKIS & WILEY CAPITAL MANAGEMENT LLC	0	502,770	0	Against
C WorldWide Asset Management Fondsmaeglerselskab A/S	0	490,329	0	Against
683 Capital Management, LLC	0	462,202	0	Against
PARAMETRIC PORTFOLIO ASSOCIATES LLC	0	380,323	0	Against
HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND	0	365,329	0	Against
MELLON INVESTMENTS Corp	330,238	0	0	For
Goldman Sachs	296,846	19,742	0	For
Connor, Clark & Lunn Investment Management Ltd.	0	307,582	0	Against

Showing the 25 largest of 352 asset managers. See all 352 in the interactive database.

2. Approve the Company's 2026 Employee Stock Purchase Plan

COMPENSATIONMajority of the votes cast: yes

Meeting held 2026-06-04.

Combines 3 wordings of this item as funds reported it.

99.2% Majority: yes · of votes cast

FOR 99.2%

FOR: 67,098,699AGAINST: 532,525

Sarepta Therapeutics, Inc.’s own tally for this item (“Proposal 4: Approval of the Company 's 2026 Employee Stock Purchase Plan The stockholders approved the 2026 ESPP”): 67,098,699 for, 532,525 against, per its Form 8-K filed 2026-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 105,571,146 outstanding shares: 64% for, 0.6% against (64% of the company cast a for/against vote).

The 80 asset managers below cast 99.9% of the shares they voted on this item FOR (37,056,838 for, 21,246 against).

FOR 99.7%

FOR: 37,056,838 (99.7%)AGAINST: 21,246 (0.1%)NOT VOTED: 74,235 (0.2%)

Largest asset managers voting on “Approve the Company's 2026 Employee Stock Purchase Plan” at Sarepta Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	11,435,342	5	For
BlackRock	8,346,572	0	For
State Street	4,827,563	0	For
First Trust	3,902,738	0	For
Fidelity	1,768,057	0	For
Federated Hermes	1,313,710	0	For
Aberdeen	961,017	0	For
Charles Schwab	672,018	0	For
T. Rowe Price	599,920	0	For
EA Series Trust	298,866	0	For
Columbia Threadneedle	220,518	0	For
Jackson National	187,511	0	For
Principal	170,378	0	For
TIAA	170,199	0	For
WisdomTree	165,136	0	For
Prudential/PGIM	154,056	0	For
HOTCHKIS & WILEY FUNDS /DE/	143,400	0	For
Pacific Life	122,989	0	For
Northwestern Mutual	112,036	0	For
Dimensional	110,633	0	For
Empower	32,200	0	Not Voted
American Century	94,968	0	For
Harbor ETF Trust	94,665	0	For
BNY Mellon	88,533	0	For
JPMorgan	86,896	0	For

Showing the 25 largest of 80 asset managers. See all 80 in the interactive database.

3. Approve the Company's 2026 Equity Incentive Plan

COMPENSATIONMajority of the votes cast: yes

Meeting held 2026-06-04.

Combines 2 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%

FOR: 63,233,193AGAINST: 4,395,283

Sarepta Therapeutics, Inc.’s own tally for this item (“Proposal 3: Approval of the Company 's 2026 Equity Incentive Plan The stockholders approved the 2026 Plan”): 63,233,193 for, 4,395,283 against, per its Form 8-K filed 2026-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 105,571,146 outstanding shares: 60% for, 4% against (64% of the company cast a for/against vote).

The 78 asset managers below cast 96% of the shares they voted on this item FOR (35,469,473 for, 1,571,908 against).

FOR 96%

FOR: 35,469,473 (95.8%)AGAINST: 1,571,908 (4.2%)

Largest asset managers voting on “Approve the Company's 2026 Equity Incentive Plan” at Sarepta Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	11,402,573	32,770	For
BlackRock	8,346,572	0	For
State Street	4,820,872	6,691	For
First Trust	3,902,738	0	For
Fidelity	1,768,057	0	For
Federated Hermes	0	1,313,710	Against
Aberdeen	961,017	0	For
Charles Schwab	672,018	0	For
T. Rowe Price	599,920	0	For
EA Series Trust	298,866	0	For
Columbia Threadneedle	220,518	0	For
Jackson National	187,511	0	For
Principal	170,378	0	For
TIAA	170,199	0	For
WisdomTree	165,136	0	For
Prudential/PGIM	63,556	90,500	Against
HOTCHKIS & WILEY FUNDS /DE/	143,400	0	For
Pacific Life	5,599	117,390	Against
Northwestern Mutual	112,036	0	For
Dimensional	110,633	0	For
American Century	94,968	0	For
Harbor ETF Trust	94,665	0	For
BNY Mellon	88,533	0	For
JPMorgan	86,896	0	For
ALPS ETF Trust	85,469	0	For

Showing the 25 largest of 78 asset managers. See all 78 in the interactive database.

4. To elect, as Class I directors to hold office until the 2028 Annual Meeting of Stockholders and until their successors are elected and qualified or their earlier death, resignation or removal, the following director nominees: Deirdre Connelly

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-06-04.

Combines 4 wordings of this item as funds reported it.

79% Majority: yes · of votes cast

FOR 79%AGAINST 21%

FOR: 53,419,881AGAINST: 14,213,242

Sarepta Therapeutics, Inc.’s own tally for this item (“Elect Director: Deirdre Connelly”): 53,419,881 for, 14,213,242 against, per its Form 8-K filed 2026-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 105,571,146 outstanding shares: 50.6% for, 13% against (64% of the company cast a for/against vote).

The 77 asset managers below cast 76% of the shares they voted on this item FOR (28,061,001 for, 8,980,479 against).

FOR 76%AGAINST 24%

FOR: 28,061,001 (75.6%)AGAINST: 8,980,479 (24.2%)ABSTAIN: 21,241 (0.1%)NOT VOTED: 74,235 (0.2%)

Largest asset managers voting on “To elect, as Class I directors to hold office until the 2028 Annual Meeting of Stockholders and until their su” at Sarepta Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	11,435,304	43	For
BlackRock	253,077	8,093,495	Against
State Street	4,827,563	0	For
First Trust	3,902,738	0	For
Fidelity	1,723,350	44,707	For
Federated Hermes	1,313,710	0	For
Aberdeen	961,017	0	For
Charles Schwab	672,018	0	For
T. Rowe Price	0	599,920	Against
EA Series Trust	298,866	0	For
Columbia Threadneedle	220,518	0	For
Jackson National	187,511	0	For
Principal	170,378	0	For
TIAA	170,199	0	For
WisdomTree	165,136	0	For
Prudential/PGIM	154,056	0	For
HOTCHKIS & WILEY FUNDS /DE/	143,400	0	For
Pacific Life	117,390	5,599	For
Northwestern Mutual	35,851	76,185	Against
Dimensional	110,633	0	For
Empower	32,200	0	Not Voted
American Century	94,968	0	For
Harbor ETF Trust	94,665	0	For
BNY Mellon	88,533	0	For
JPMorgan	86,896	0	For

Showing the 25 largest of 77 asset managers. See all 77 in the interactive database.

5. To elect, as Class I directors to hold office until the 2028 Annual Meeting of Stockholders and until their successors are elected and qualified or their earlier death, resignation or removal, the following director nominees: Douglas S. Ingram

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-06-04.

Combines 4 wordings of this item as funds reported it.

99% Majority: yes · of votes cast

FOR 99%

FOR: 66,812,593AGAINST: 827,973

Sarepta Therapeutics, Inc.’s own tally for this item (“Elect Director: Douglas S. Ingram”): 66,812,593 for, 827,973 against, per its Form 8-K filed 2026-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 105,571,146 outstanding shares: 63% for, 0.8% against (64% of the company cast a for/against vote).

The 77 asset managers below cast 99.8% of the shares they voted on this item FOR (36,978,870 for, 62,609 against).

FOR 99.5%

FOR: 36,978,870 (99.6%)AGAINST: 62,609 (0.2%)ABSTAIN: 21,241 (0.1%)NOT VOTED: 74,235 (0.2%)

Largest asset managers voting on “To elect, as Class I directors to hold office until the 2028 Annual Meeting of Stockholders and until their su” at Sarepta Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	11,402,612	32,733	For
BlackRock	8,346,572	0	For
State Street	4,820,872	6,691	For
First Trust	3,902,738	0	For
Fidelity	1,768,057	0	For
Federated Hermes	1,313,710	0	For
Aberdeen	961,017	0	For
Charles Schwab	672,018	0	For
T. Rowe Price	599,920	0	For
EA Series Trust	298,866	0	For
Columbia Threadneedle	220,518	0	For
Jackson National	187,511	0	For
Principal	170,378	0	For
TIAA	170,199	0	For
WisdomTree	165,136	0	For
Prudential/PGIM	154,056	0	For
HOTCHKIS & WILEY FUNDS /DE/	143,400	0	For
Pacific Life	122,989	0	For
Northwestern Mutual	112,036	0	For
Dimensional	110,633	0	For
Empower	32,200	0	Not Voted
American Century	94,968	0	For
Harbor ETF Trust	94,665	0	For
BNY Mellon	88,533	0	For
JPMorgan	86,896	0	For

Showing the 25 largest of 77 asset managers. See all 77 in the interactive database.

6. To elect, as Class I directors to hold office until the 2028 Annual Meeting of Stockholders and until their successors are elected and qualified or their earlier death, resignation or removal, the following director nominees: Hans Wigzell, M.D., Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-06-04.

Combines 4 wordings of this item as funds reported it.

84% Majority: yes · of votes cast

FOR 84%AGAINST 16%

FOR: 56,984,756AGAINST: 10,663,180

Sarepta Therapeutics, Inc.’s own tally for this item (“Elect Director: Hans Wigzell, M.D., Ph.D.”): 56,984,756 for, 10,663,180 against, per its Form 8-K filed 2026-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 105,571,146 outstanding shares: 54.0% for, 10% against (64% of the company cast a for/against vote).

The 77 asset managers below cast 85% of the shares they voted on this item FOR (31,387,500 for, 5,653,980 against).

FOR 85%AGAINST 15%

FOR: 31,387,500 (84.5%)AGAINST: 5,653,980 (15.2%)ABSTAIN: 21,241 (0.1%)NOT VOTED: 74,235 (0.2%)

Largest asset managers voting on “To elect, as Class I directors to hold office until the 2028 Annual Meeting of Stockholders and until their su” at Sarepta Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	11,384,461	50,886	For
BlackRock	8,346,572	0	For
State Street	9,598	4,817,965	Against
First Trust	3,902,738	0	For
Fidelity	1,768,057	0	For
Federated Hermes	1,313,710	0	For
Aberdeen	961,017	0	For
Charles Schwab	672,018	0	For
T. Rowe Price	0	599,920	Against
EA Series Trust	298,866	0	For
Columbia Threadneedle	220,518	0	For
Jackson National	187,511	0	For
Principal	170,378	0	For
TIAA	170,199	0	For
WisdomTree	165,136	0	For
Prudential/PGIM	154,056	0	For
HOTCHKIS & WILEY FUNDS /DE/	143,400	0	For
Pacific Life	122,989	0	For
Northwestern Mutual	0	112,036	Against
Dimensional	110,633	0	For
Empower	32,200	0	Not Voted
American Century	94,968	0	For
Harbor ETF Trust	94,665	0	For
BNY Mellon	88,533	0	For
JPMorgan	86,896	0	For

Showing the 25 largest of 77 asset managers. See all 77 in the interactive database.

7. To elect, as Class I directors to hold office until the 2028 Annual Meeting of Stockholders and until their successors are elected and qualified or their earlier death, resignation or removal, the following director nominees: Kathryn J. Boor, Ph.D.

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-06-04.

Combines 4 wordings of this item as funds reported it.

94% Majority: yes · of votes cast

FOR 94%

FOR: 63,915,239AGAINST: 3,722,626

Sarepta Therapeutics, Inc.’s own tally for this item (“Elect Director: Kathryn J. Boor, Ph.D.”): 63,915,239 for, 3,722,626 against, per its Form 8-K filed 2026-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 105,571,146 outstanding shares: 61% for, 4% against (64% of the company cast a for/against vote).

The 77 asset managers below cast 98% of the shares they voted on this item FOR (36,286,074 for, 755,406 against).

FOR 98%

FOR: 36,286,074 (97.7%)AGAINST: 755,406 (2.0%)ABSTAIN: 21,241 (0.1%)NOT VOTED: 74,235 (0.2%)

Largest asset managers voting on “To elect, as Class I directors to hold office until the 2028 Annual Meeting of Stockholders and until their su” at Sarepta Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	11,402,579	32,767	For
BlackRock	8,346,572	0	For
State Street	4,821,092	6,471	For
First Trust	3,902,738	0	For
Fidelity	1,768,057	0	For
Federated Hermes	1,313,710	0	For
Aberdeen	961,017	0	For
Charles Schwab	672,018	0	For
T. Rowe Price	0	599,920	Against
EA Series Trust	298,866	0	For
Columbia Threadneedle	220,518	0	For
Jackson National	187,511	0	For
Principal	170,378	0	For
TIAA	170,199	0	For
WisdomTree	165,136	0	For
Prudential/PGIM	154,056	0	For
HOTCHKIS & WILEY FUNDS /DE/	143,400	0	For
Pacific Life	122,989	0	For
Northwestern Mutual	35,851	76,185	Against
Dimensional	110,633	0	For
Empower	32,200	0	Not Voted
American Century	94,968	0	For
Harbor ETF Trust	94,665	0	For
BNY Mellon	88,533	0	For
JPMorgan	86,896	0	For

Showing the 25 largest of 77 asset managers. See all 77 in the interactive database.

8. To elect, as Class I directors to hold office until the 2028 Annual Meeting of Stockholders and until their successors are elected and qualified or their earlier death, resignation or removal, the following director nominees: Michael Chambers

DIRECTOR ELECTIONSMajority of the votes cast: yes

Meeting held 2026-06-04.

Combines 4 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 65,892,431AGAINST: 1,752,077

Sarepta Therapeutics, Inc.’s own tally for this item (“Elect Director: Michael Chambers”): 65,892,431 for, 1,752,077 against, per its Form 8-K filed 2026-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 105,571,146 outstanding shares: 62% for, 2% against (64% of the company cast a for/against vote).

The 77 asset managers below cast 99.7% of the shares they voted on this item FOR (36,946,352 for, 95,127 against).

FOR 99.4%

FOR: 36,946,352 (99.5%)AGAINST: 95,127 (0.3%)ABSTAIN: 21,241 (0.1%)NOT VOTED: 74,235 (0.2%)

Largest asset managers voting on “To elect, as Class I directors to hold office until the 2028 Annual Meeting of Stockholders and until their su” at Sarepta Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Vote
Vanguard	11,402,603	32,742	For
BlackRock	8,346,572	0	For
State Street	4,821,092	6,471	For
First Trust	3,902,738	0	For
Fidelity	1,768,057	0	For
Federated Hermes	1,313,710	0	For
Aberdeen	961,017	0	For
Charles Schwab	672,018	0	For
T. Rowe Price	567,191	32,729	For
EA Series Trust	298,866	0	For
Columbia Threadneedle	220,518	0	For
Jackson National	187,511	0	For
Principal	170,378	0	For
TIAA	170,199	0	For
WisdomTree	165,136	0	For
Prudential/PGIM	154,056	0	For
HOTCHKIS & WILEY FUNDS /DE/	143,400	0	For
Pacific Life	122,989	0	For
Northwestern Mutual	112,036	0	For
Dimensional	110,633	0	For
Empower	32,200	0	Not Voted
American Century	94,968	0	For
Harbor ETF Trust	94,665	0	For
BNY Mellon	88,533	0	For
JPMorgan	86,896	0	For

Showing the 25 largest of 77 asset managers. See all 77 in the interactive database.

9. Ratify the selection of KPMG LLP as the Company's independent registered public accounting firm for the current year ending December 31, 2026

AUDIT-RELATEDMajority of the votes cast: yes

Meeting held 2026-06-04.

Combines 3 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%

FOR: 79,907,368AGAINST: 2,110,136

Sarepta Therapeutics, Inc.’s own tally for this item (“Proposal 5: Ratification of KPMG as the Company 's Independent Registered Public Accounting Firm The stockholders ratified the appointment of KPMG LLP as the Company's independent registered public accounting firm for th”): 79,907,368 for, 2,110,136 against, per its Form 8-K filed 2026-06-04 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item. Of all 105,571,146 outstanding shares: 76% for, 2% against (78% of the company cast a for/against vote).

The 77 asset managers below cast 99.9% of the shares they voted on this item FOR (37,015,448 for, 26,030 against).

FOR 99.6%

FOR: 37,015,448 (99.7%)AGAINST: 26,030 (0.1%)ABSTAIN: 21,242 (0.1%)NOT VOTED: 74,235 (0.2%)

Largest asset managers voting on “Ratify the selection of KPMG LLP as the Company's independent registered public accounting firm for the curren” at Sarepta Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Vote
Vanguard	11,417,274	18,071	1	For
BlackRock	8,346,572	0	0	For
State Street	4,825,433	2,130	0	For
First Trust	3,902,738	0	0	For
Fidelity	1,768,057	0	0	For
Federated Hermes	1,313,710	0	0	For
Aberdeen	961,017	0	0	For
Charles Schwab	672,018	0	0	For
T. Rowe Price	599,920	0	0	For
EA Series Trust	298,866	0	0	For
Columbia Threadneedle	220,518	0	0	For
Jackson National	187,511	0	0	For
Principal	170,378	0	0	For
TIAA	170,199	0	0	For
WisdomTree	165,136	0	0	For
Prudential/PGIM	154,056	0	0	For
HOTCHKIS & WILEY FUNDS /DE/	143,400	0	0	For
Pacific Life	122,989	0	0	For
Northwestern Mutual	112,036	0	0	For
Dimensional	110,633	0	0	For
Empower	32,200	0	0	Not Voted
American Century	94,968	0	0	For
Harbor ETF Trust	94,665	0	0	For
BNY Mellon	88,533	0	0	For
JPMorgan	86,896	0	0	For

Showing the 25 largest of 77 asset managers. See all 77 in the interactive database.

10. Advisory vote to approve, on a non-binding basis, named executive officer compensation

SECTION 14A SAY-ON-PAY VOTES

Reported under meeting date 2026-04-08; no official results on file for that date.

100% fund support · no official result

FOR 100%

The 2 asset managers below cast 100% of the shares they voted on this item FOR (111,887 for, 0 against).

FOR: 111,887 (100.0%)

Largest asset managers voting on “Advisory vote to approve, on a non-binding basis, named executive officer compensation” at Sarepta Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
SCHRODER INVESTMENT MANAGEMENT GROUP	102,222	0	0	0	For
Robertson Stephens Wealth Management, LLC	9,665	0	0	0	For

11. Approve Omnibus Stock Plan

COMPENSATIONMajority of the votes cast: yes

Meeting held 2026-06-04.

99.2% Majority: yes · of votes cast

FOR 99.2%

FOR: 67,098,699AGAINST: 532,525

The 2 asset managers below cast 100% of the shares they voted on this item FOR (36,700 for, 0 against).

FOR 33%NOT VOTED 67%

FOR: 36,700 (33.1%)NOT VOTED: 74,235 (66.9%)

Largest asset managers voting on “Approve Omnibus Stock Plan” at Sarepta Therapeutics, Inc., 2025-2026
Asset manager	For	Against	Abstain	Withheld	Vote
Empower	32,200	0	0	0	Not Voted
CLEARWATER INVESTMENT TRUST	4,500	0	0	0	For

Largest Sarepta Therapeutics, Inc. shareholders voting in 2025-2026

Ranked by the number of Sarepta Therapeutics, Inc. shares each manager voted on the most widely held ballot item of the 2025-2026 meeting, shown as a share of the 105,571,146 shares outstanding at the time of that meeting.

Top Sarepta Therapeutics, Inc. shareholders by shares voted, 2025-2026
#	Asset manager	% of shares outstanding
1	Vanguard	11.69%
2	BlackRock	10.47%
3	State Street	5.90%
4	First Trust	3.72%
5	RA CAPITAL MANAGEMENT, L.P.	3.70%
6	Aberdeen	3.11%
7	Federated Hermes	2.89%
8	AQR	2.12%
9	GEODE CAPITAL MANAGEMENT, LLC	1.81%
10	T. Rowe Price	1.78%

Reported Sarepta Therapeutics, Inc. ownership

Positions disclosed to the SEC on Schedules 13D and 13G, Form 13F and the company’s own proxy statement (DEF 14A).

Sarepta Therapeutics, Inc. beneficial owners on record for the 2025-2026 proxy season
Holder	% outstanding	Disclosure
Shares Outstanding as of 4/8/2026	100.00%	DEF14A
BlackRock, Inc.	15.76%	13G
Vanguard Group	11.19%	13F
STATE STREET CORPORATION	8.45%	13G
Vanguard Portfolio Management	8.05%	13G
Entities Affiliated with AQR Capital Management	7.68%	DEF14A
AQR Capital Management, LLC	5.05%	13G
Two Sigma	4.35%	13F
Richard J. Barry	3.08%	DEF14A
Douglas S. Ingram	2.45%	DEF14A

Percentages above are of 105,571,146 shares outstanding, as reported by Sarepta Therapeutics, Inc. on its Form 10-Q dated 2026-03-31 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, so the percentages are the ones that were true then, not ones restated against today’s share count.

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered investment companies and institutional managers disclose how they voted every proxy, and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Sarepta Therapeutics, Inc.’s 10-Q dated 2026-03-31. This page is a static snapshot rebuilt weekly on 02 October 2026; a live search always shows the current data.

At Sarepta Therapeutics, Inc.'s shareholder meeting held 2026-06-04, in the 2025-2026 proxy season, 356 asset managers reported how they voted in their SEC Form N-PX filings, covering 3,299 separate fund positions. Their filings are grouped here into 11 reported items; because filers word the same ballot item differently, that can be more than the number of items on the ballot. On the most widely held item on that ballot — Advisory vote to approve, on a non- binding basis, named executive officer compensation — FOR was 67% of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side), which is more than half. Whether the item was approved is for the filing to say; that statement has not been read for this item. Source: Sarepta Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on 2026-06-04.

Sarepta Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).